FibroBiologics Advances Bone Marrow Organoid Platform Offering New Treatment Options For Hematopoietic Cancers And Age-Related Immune Decline

FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced significant advancements in its Bone Marrow Organoid platform, which may offer promising new treatment options for hematopoietic cancers and age-related immune decline.

The company's proprietary Bone Marrow Organoids have demonstrated potential in multiple therapeutic applications:

• Our Pre-IND animal trials show that Transplantation of Bone Marrow Organoids into xenografted melanoma mouse model significantly reduced tumor size.
• The organoids enable efficient ex vivo gene editing, allowing for swift and targeted therapeutic interventions before transplantation.
• FibroBiologics' Bone Marrow Organoids can be cryopreserved, offering a scalable and readily available treatment option for bone marrow transplantation.